Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting
Rhea-AI Summary
Myriad Genetics (NASDAQ: MYGN) will present four research abstracts at the Society of Gynecologic Oncology Annual Meeting, April 10-13, 2026, in San Juan, Puerto Rico.
Key highlights: Precise MRD data showed post‑adjuvant ctDNA levels were significantly prognostic of ovarian cancer recurrence; three additional studies use the Myriad Collaborative Research Registry™ with de‑identified data from >1.3 million participants. Presentations and posters occur April 11–13; Myriad will exhibit at booth #523.
Positive
- None.
Negative
- None.
News Market Reaction – MYGN
On the day this news was published, MYGN declined 6.92%, reflecting a notable negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $31M from the company's valuation, bringing the market cap to $416.58M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MYGN is up 0.63% while key diagnostics peers like FLGT, CDNA, CSTL, PSNL and NEO show declines between -2.55% and -5.66%, indicating a stock‑specific move rather than a sector‑wide shift.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | FDA CDx approval | Positive | -2.9% | FDA approved MyChoice CDx as Zejula companion diagnostic in ovarian cancer. |
| Mar 02 | Product launch | Positive | +5.6% | Commercial launch of Precise MRD with select community oncologists for breast cancer. |
| Feb 24 | Clinical data abstracts | Positive | +1.1% | Six ASCO‑GU abstracts on Precise MRD, Prolaris, and MyRisk clinical performance. |
| Feb 23 | Earnings, guidance | Neutral | +1.1% | Q4 and 2025 results with $824.5M revenue and reiterated 2026 guidance and margins. |
| Feb 19 | Test validation data | Positive | +0.2% | FirstGene prenatal screen showed ≥98.2% sensitivity and ≥99.0% specificity across components. |
Positive clinical, launch, and approval news has usually seen mildly positive price reactions, with one notable selloff on FDA approval.
Over the last few months, Myriad reported several oncology-focused milestones, including FDA approval of MyChoice CDx for Zejula in ovarian cancer on Mar 17, 2026, commercial launch of Precise MRD on Mar 2, 2026, and multiple abstract presentations at ASCO‑GU. Q4 and full‑year 2025 results on Feb 23, 2026 showed $824.5M in annual revenue and reiterated 2026 guidance. Today’s SGO abstracts extend this pattern of oncology data releases, particularly around Precise MRD and registry‑based insights.
Regulatory & Risk Context
An effective shelf prospectus dated February 24, 2026 registers up to $200,000,000 of common stock, preferred stock, depositary shares, debt securities and warrants for potential sale over time, with proceeds earmarked for general corporate purposes including operations, R&D, possible debt repayment and acquisitions.
Market Pulse Summary
The stock moved -6.9% in the session following this news. A negative reaction despite this clinically focused news would contrast with earlier data‑driven announcements that generally saw aligned or mildly positive moves, with only the FDA CDx approval drawing a -2.93% decline. The SGO presentations extend the Precise MRD story and leverage a registry of more than 1.3 million participants, but shares remain below the $6.08 200‑day MA and the existing $200,000,000 shelf could add an overhang if investors focus on potential capital raises.
Key Terms
molecular residual disease medical
ctDNA medical
ultrasensitive assay medical
germline pathogenic medical
lynch syndrome medical
hereditary cancer screening medical
pan-cancer medical
poster board technical
AI-generated analysis. Not financial advice.
SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting, including two oral presentations and two posters.
“Having four abstracts accepted at the prestigious SGO annual meeting underscores the importance of the data we are sharing and our commitment to the cancer care continuum,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics. “We are particularly pleased to be presenting the latest Precise MRD™ data, showing that Precise MRD testing after adjuvant therapy for ovarian cancer was significantly prognostic of recurrence during the monitoring period. Importantly, recurrence risk tracked with the quantitative ctDNA fraction detected by Precise MRD, with elevated risk observed even at ctDNA levels detectable only by an ultrasensitive assay.”
The remaining three presentations use data from the Myriad Collaborative Research Registry™ (MCRR), one of the largest pan-cancer registries accessible for research use, including de-identified data for more than 1.3 million participants. The studies demonstrate Myriad’s commitment to externally driven research that addresses diverse questions with immediate clinical implications:
- Germline pathogenic and likely pathogenic variant prevalence is associated with age and ancestry in patients diagnosed with ovarian cancer before age 40;
- Ovarian cancer diagnosis varies by Lynch syndrome gene, informing counseling and risk-reducing surgery recommendations;
- Universal hereditary cancer screening identifies more individuals at high risk for endometrial cancer compared to age-based screening.
These studies will be presented at the Society of Gynecologic Oncology Annual Meeting on April 10-13 at the Puerto Rico Convention Center in San Juan. Myriad will exhibit at booth #523. For more information, visit: https://myriad.com/oncology/oncology-conferences/
Myriad Genetics Presentations
Precise MRD
Evaluation of the Relationship of Molecular Residual Disease Testing to Ovarian Cancer Recurrence
Poster Board Number: 1590
Sun., April 12 at 12:00-1:00 pm AST
Presenter: John Nakayama, MD, Allegheny Health Network
MCRR
Prevalence of germline pathogenic variants in patients with endometrial cancer diagnosed before and after 65 years old within a laboratory-based research registry
Rapid Fire Oral I: Genetics Prevention and Surgery
Sat., April 11 – 3:05-3:08 pm AST
Presenter: Kieran Seay, MD, University of Pittsburgh Medical Center
Broad landscape of genetic variants and ancestry associated with ovarian cancer before age forty
Poster Board Number: 1450
Sun., April 12 – 4:00-4:45 pm AST
Presenter: Eliya K. Shachar, MD, University of California, Los Angeles
Age at ovarian cancer diagnosis varies by lynch syndrome gene: a genetic testing laboratory registry study
Focused Forum X: Genetics - Keeping up with the Genes
Mon., April 13 – 9:30-10:30 am AST
Presenter: Ying L. Liu, MD, MPH, Memorial Sloan Kettering Cancer Center
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit myriad.com.
Myriad Genetics Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements that the studies demonstrate the company’s commitment to externally driven research that addresses diverse questions with immediate clinical implications. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 24, 2026, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
